Stocks · News reference

8-K filing — X4 Pharmaceuticals, Inc (XFOR)

Sep 8, 2026, 11:15 AMSEC EDGAR

Filed: 2026-09-08 AccNo: 0001501697-26-000072 Size: 158 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: edgar
Observed: Sep 8, 2026, 11:15 AM
Checked: Sep 8, 2026, 11:15 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 8, 2026, 2:28 PMBenzinga Newsdesk
X4 Pharmaceuticals shares are trading lower. The company announced the FDA’s agreement to reduce the 4WARD Phase 3 trial sample size. Enrollment is expected to finish by year-end 2026, with topline data in H1 2028.
XFOR
BenzingaSep 8, 2026, 11:04 AMBenzinga Newsdesk
X4 Pharmaceuticals Says FDA Agreed To Reduce Phase 3 4WARD Chronic Neutropenia Trial Size From 176 To 126 Participants; Expects Enrollment Completion By Year-End 2026, Topline Data In H1 2028
XFOR
BenzingaAug 26, 2026, 4:54 PMBenzinga Newsdesk
FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat Congenital
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=919722
XFOR